STAT3 and gastric cancer: In vivo research revealed that circUBE2Q2 knockdown in conjunction with a STAT3 inhibitor synergistically suppresses the growth of GC, indicating that circUBE2Q2 targeting may improve the efficacy of targeted therapies (Yang et al., 2021).